Inhibikase Therapeutics Inc’s recent filing unveils that its 10% Owner Sands Capital Life Sciences Pu acquired Company’s shares for reported $3.0 million on Nov 21 ’25. In the deal valued at $1.45 per share,2,068,965 shares were bought. As a result of this transaction, Sands Capital Life Sciences Pu now holds 13,018,965 shares worth roughly $20.05 million.
Cantor Fitzgerald initiated its Inhibikase Therapeutics Inc [IKT] rating to an Overweight in a research note published on December 11, 2025; the price target was $4. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in mid February from “a Buy” to “a Neutral”.
Price Performance Review of IKT
On Friday, Inhibikase Therapeutics Inc [NASDAQ:IKT] saw its stock jump 0.98% to $1.54. Over the last five days, the stock has gained 2.67%. Inhibikase Therapeutics Inc shares have fallen nearly -51.88% since the year began. Nevertheless, the stocks have fallen -52.62% over the past one year. While a 52-week high of $4.20 was reached on 01/02/25, a 52-week low of $1.33 was recorded on 11/03/25.
Levels Of Support And Resistance For IKT Stock
The 24-hour chart illustrates a support level at 1.5067, which if violated will result in even more drops to 1.4733. On the upside, there is a resistance level at 1.5667. A further resistance level may holdings at 1.5933.
How much short interest is there in Inhibikase Therapeutics Inc?
A steep rise in short interest was recorded in Inhibikase Therapeutics Inc stocks on 2025-11-28, growing by 1.11 million shares to a total of 4.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 3.03 million shares. There was a rise of 26.9%, which implies that there is a positive sentiment for the stock.
